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Increased mucosa-associated E.coli are present in Crohn’s disease but their role in 
pathogenesis is uncertain.  
Aims 
To assess efficacy and safety of an antibiotic/hydroxychloroquine combination effective 
against E.coli inside macrophages.   
Methods 
Adults with moderately active disease (CDAI>220-450 plus C reactive protein≥5mg/l and/or 
faecal calprotectin >250ug/g) were randomised to receive (open label) oral budesonide 
(Entocort CR 9mg/day 8 weeks, 6mg/day 2 weeks, 3mg/day 2 weeks) or oral ciprofloxacin  
500mg bd, doxycycline 100mg bd, hydroxychloroquine 200mg tds for 4 weeks, followed by 
doxycycline 100mg bd and hydroxychloroquine 200mg tds for 20 weeks. Primary endpoints 
were remission (CDAI</=150) at 10 weeks, remission maintained to 24 weeks, and remission 
maintained to 52 weeks. Patients not responding (CDAI fall by >70) by 10 weeks were 
invited to cross-over onto the alternative therapy. 
Results 
Fifty-nine patients were recruited across 8 sites. Including cross-over, 39 patients received 
antibiotics/hydroxychloroquine and 39 received budesonide. At 10 weeks, 24 weeks, 52 
weeks on initial therapy only 2/27, 2/27, 1/27 were in remission on 
antibiotics/hydroxychloroquine compared with 8/32, 1/32, 1/32 on budesonide (P=0.092 at 
10 weeks). Withdrawals by 10 weeks due to adverse events were seen in 15 receiving 
antibiotics/hydroxychloroquine and 6 budesonide. Results including crossover were more 
promising with 9/24 patients receiving antibiotics/hydroxychloroquine per protocol in 
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remission by 24 weeks.    No correlation was seen between response to 
antibiotics/hydroxychloroquine and ASCA/OmpC antibody status or disease location. 
Conclusion 
Overall results with this antibiotic/hydroxychloroquine combination were unimpressive but 
long-term remission is seen in some patients and justifies further study. 
 
Registered at ClinicalTrials.gov NCT01783106 
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Mucosa-associated E. coli are found in Crohn’s disease adherent to the intestinal epithelial 
surface [1],  within granulomas [2], mesenteric lymph-nodes [3] and in peripheral blood 
[4].In the laboratory they translocate across the microfold (M) cells that overlie Peyer’s 
patches and colonic lymphoid follicles [5,6]. They replicate within macrophage vesicles [7,8] 
and induce granulomas [9]. They lack any consistent genotype [10], and it is unclear 
whether they are part of the pathogenic process or merely secondary bystanders.  
 
Proof of a pathogenic role depends on showing that therapy targeted to eradicate E. coli is 
beneficial. This entails killing the bacteria replicating within macrophage vesicles [11]. This is 
not straightforward for some antibiotics such as penicillins and gentamicin are unable to 
penetrate macrophages. In Crohn’s disease meta-analysis has not shown convincing benefit 
with antibiotics [12]. However, there are positive signals with rifaximin [13], ciprofloxacin 
(as single agent in one study [14] but usually in combination with metronidazole) [15], and 
azithromycin with metronidazole [16]. None of these effects have been sufficiently clear for 
antibiotic therapy to become “mainstream”. 
 
Whipple’s disease, caused by Tropheryma whipplei, and Q-fever, caused by Coxiella burnetii, 
are both unequivocally due to replication of bacteria within intestinal macrophages and are 
difficult to cure even with long-term antibiotics. One effective strategy is to combine long-
term doxycycline, with the antimalarial hydroxychloroquine [17,18]. The rationale for 
hydroxychloroquine is that many bacteria, including Crohn’s disease mucosal E. coli, require 
an acid environment to replicate [8]. Hydroxychloroquine is a mild base that enters 
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macrophage vesicles and reverses their normal acidification [19]. In the laboratory this 
substantially enhances killing of E. coli by macrophages [20].  
 
We have therefore assessed the efficacy and safety of a combination of short-term 
ciprofloxacin and longer-term doxycycline with hydroxychloroquine in the treatment of 
active Crohn’s disease. Budesonide was prescribed as comparator as this was standard care 
for patients with moderately active Crohn’s disease at the inception of this trial (2013) [21].   
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Materials and Methods 
Study design 
This was an open-label investigator-led randomised controlled trial in adults with moderate 
to severe Crohn’s disease. The aim was to provide an unbiased estimate of the remission 
rate for the antibiotic/hydroxychloroquine combination to inform subsequent phase 3 trial 
design. Patients were recruited from 8 Hospitals in England between 2013 and 2018.  
The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as 
reflected in a priori approval by the North West-Liverpool East Research Ethics Committee 
of the NHS Health Research Authority on February 6th, 2012 (08/H1002/71). Ethics approval 
required use of standard-of-care at the time of application as comparator rather than 
placebo.  The study was co-sponsored by University of Liverpool and the Royal Liverpool and 
Broadgreen Hospitals University Trust and adopted onto the National Institute for Health 
Research portfolio of supported clinical research studies. An independent Data Monitoring 
Committee monitored the trial at approximately 6month intervals. All patients gave 
informed written consent. 
Participants 
Eligible patients were aged ≥18 with moderately active Crohn’s disease (CDAI>220-450) 
involving small intestine, colon, or both, with serum C reactive protein (CRP) >5mg/l and/or 
faecal calprotectin >250 microgram/gram. Patients receiving thiopurines had to have stable 
dose for ≥ 3 months. Patients receiving anti-TNF, other biologics, or methotrexate within 
previous 3 months were excluded. Concurrent use of prednisolone >5mgs/day or 
budesonide >3mg/day was also excluded as were patients receiving antibiotics within the 
previous 4 weeks. Patients receiving mesalazine must have a stable dose for at least one 
month. 
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Randomisation and stratification 
Patients were randomised centrally 1:1 to either antibiotic/hydroxychloroquine 
combination or budesonide (Entocort CR©). Patients were stratified prior to randomisation 
into four groups: isolated colonic Crohn’s disease versus small intestine + colon, 
immunosuppression (thiopurines) versus no immunosuppression.  Randomisation was by 
random number generation in Microsoft Excel, in blocks of 10 patients (by sequence of 
joining trial) within these four groups. Opaque allocation envelopes labelled by patient 
number were filled by the trial statistician at a remote site and posted to the trial co-
ordinator.  
Interventions and crossover 
Patients randomised to antibiotics/hydroxychloroquine received oral ciprofloxacin 500mg 
bd, doxycycline 100mg bd, hydroxychloroquine 200mg tds before meals for 4 weeks 
followed by 20 weeks continued therapy with doxycycline 100mg bd and 
hydroxychloroquine 200mg tds. Patients randomised to budesonide received oral 
budesonide (Entocort CR©) 9mg/day taken in the morning for 8 weeks followed by 
6mg/day for 2 weeks as per Rutgeerts et al [22] followed by 3 mg/day for a further 2 weeks 
as per current standard steroid tailing practice. Patients failing to respond (CDAI fall by >70) 
by 10 weeks were offered crossover onto the alternative treatment (Figure 1). 
Outcomes 
The primary endpoint was remission (CDAI <150) without addition of any other treatment 
for Crohn’s disease and assessed at three time points: 10 weeks; remission at 10 weeks 
maintained through to 24 weeks; remission at 10 weeks maintained through to 52 weeks. 
The 10 weeks’ time point was chosen to conform to the comparator budesonide trial data 
[22], 24 weeks to correspond with the end of the antibiotic/hydroxychloroquine therapy 
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period, and 52 weeks to determine whether any therapeutic effect might persist after 
cessation. Secondary endpoints included remission (CDAI <150) at 4 weeks, remission or 
response (CDAI fall by >70 points) at 10 weeks, patient global assessment of symptom 
severity by IBD10  (10 cm visual analogue score) [23] at 4,10,24,52 weeks, faecal 
calprotectin (assayed using whichever assay was in routine use at the recruiting site) 
10,24,52 weeks. Adverse events were assessed at each visit. 
 
Power calculation and early closure 
Budesonide was predicted to have a 53% remission rate (95% CI 43%, 64%) at 10 weeks 
[22]. A sample size of 50 in each group, was estimated to have 80% power at 5% significance 
level to detect a difference between the predicted 53% remission rate for budesonide and a 
remission rate of 80% in the antibiotic/hydroxychloroquine group. Recruitment commenced 
late 2013 and initially progressed reasonably but gradually fell below target probably due to 
increasing availability of biologics. With 59 patients recruited, 78 treatment courses with 
crossover, over the five-year recruitment period, the Data Monitoring Committee 
considered that we had data sufficient to address the primary aims of the trial and that trial 
closure was appropriate. 
Serology 
Serum samples were obtained on recruitment, blind labelled, and tested for relevant 
antibodies: OmpC (outer membrane porin C of E. coli and other Gram negative bacteria), 
FlaX, Fla2 , CBir1 (all flagellar antigens present in Clostridiales) and anti-Saccharomyces 
cerevisiae antibodies (ASCA) by quantitative ELISA performed by Prometheus® Laboratories 
Inc., San Diego as part of the Prometheus IBD sgi Diagnostic® Cat.#1800 and with reference 
to their pre-established normal ranges. 
 10 
Statistical analysis 
Primary analysis of categorical outcomes of remission at 10 weeks and maintenance of 
remission at 24 weeks and 52 weeks was by Fisher's exact test. This was also performed 
with crossover data included. A pre-planned subgroup analysis assessed the possibility that 
serology, particularly anti-Saccharomyces cerevisiae antibody (ASCA) status might predict 
response to antibiotics/hydroxychloroquine. To account for multiple testing in these 
secondary analyses, significance was set at P-values of 0.02 (Fisher's test including 
crossover) and 0.01 for the other tests, implying an overall type I error risk of approximately 
0.05 (Bonferroni calculations). Secondary outcomes were analysed using Fisher’s exact test 
for categorical outcomes, and Wilcoxon Rank Sign test for numerical values (patient global 





Eighty-three patients were screened and 61 randomised of whom 59 took the study 
medication and were eligible for participation (Supplementary Figure 1). There were no 
significant differences at baseline between the treatment groups in demographics or 
disease activity (Table 1). 
Response to therapy 
Initial therapy 
Twenty-seven patients received antibiotics and hydroxychloroquine as initial therapy and 32 
received budesonide. Response was not significantly different between 
antibiotics/hydroxychloroquine and budesonide at any of the three primary outcome 
timepoints: 10 weeks, 24 weeks and 52 weeks (Table 2). Only patients who were in 
remission at 10 weeks were eligible for the primary analyses of maintenance in remission at 
24 and 52 weeks. However, a post-hoc analysis that includes 3 patients who responded 
(CDAI fall by >70 but still >150) by 10 weeks and had gone into remission by 24 weeks on 
continued therapy showed a trend towards benefit with antibiotics/hydroxychloroquine, 
particularly when assessed per protocol (5/17 in remission at 24 weeks versus 1/26 for 
budesonide; P=0.028 [not reaching predetermined significance threshold of 0.01]. There 
was a non-significant tendency towards a higher remission rate with budesonide at 10 
weeks (8/32 versus 2/27 on intention to treat (ITT) analysis (P=0.092), but by 24 weeks only 
one budesonide-treated patient remained in remission. Only one patient in each treatment 
group remained in remission through to 52 weeks – plus one additional patient receiving 
antibiotics/hydroxychloroquine who had been a responder at 10 weeks. 
 
Initial therapy and crossover combined 
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Including crossover, there were 39 treatment courses in each group. Intention to treat 
analysis showed no significant differences in primary endpoint data at any of the three time 
points, 10, 24, and 52 weeks (Table 3, Figure 2).  
 
When analysed per protocol, and including (post hoc) the three 10 week responders who 
were in remission by 24 weeks, 9 of 24 patients receiving antibiotics/hydroxychloroquine 
were in remission at 24 weeks compared with 1 of 32 receiving budesonide (P=0.001). By 52 
weeks only one of 31 who had received budesonide per protocol remained in remission 
compared with three of 23 patients who received antibiotics/hydroxychloroquine plus one 
additional patient who had responded (CDAI fall >70 but still >150) by 10 weeks. 
 
Impact of phenotype and serology 
There was no signal that patients with isolated colonic Crohn’s disease (L2) responded 
differently to the antibiotic/hydroxychloroquine combination (Supplementary Table 1; 
P=1.0).  
 
Out of 59 patients recruited, 50 had sera available for testing, 21 were positive for ASCA, 6 
were positive for OmpC, and 26 were positive for either ASCA or OmpC.  ASCA, OmpC, 
separately or in combination, and FlaX  and CBir serology were not associated with response 
to the antibiotic/hydroxychloroquine combination (Supplementary Table 2).  
 
The phenotypic profile of the 9 patients who were in remission at 24 weeks on 
antibiotics/hydroxychloroquine showed no obvious features that might be used to predict 




Rates of remission at 4 weeks and the combined endpoint of remission or response at 10 
weeks were similar in both treatment groups, on initial therapy (Table 2) and including 
cross-over (Table 3). 
Patient global index of severity (IBD10) correlated well with CDAI (r=-0.745; P<0.0001 based 
on 219 data sets from the 59 patients) with IBD10 >8 equivalent to CDAI ≤150 (remission) as 
previously reported23 (Supplementary Figure 2). Patients showed similar improvement in 
both treatment groups. IBD10 improved from week 0 median (IQR) 3.3 (2.1-4.9) to week 10 
5.9 (4.2-8.1) with antibiotics/hydroxychloroquine (P=0.001) and from week 0 median (IQR) 
4.1 (2.2-5.3) to week 10 6.35 (2.7-9.1) with budesonide (P=0.006) (Supplementary Figure 3). 
Again there was evidence of better response at 24 weeks with 
antibiotics/hydroxychloroquine median (IQR) 8.75 (6.75-9.3) compared with budesonide 
median 6 (3.3-6.5) but numbers at this endpoint were small (n=12 
antibiotics/hydroxychloroquine; n=6 budesonide). 
 
Faecal calprotectin correlated less closely with CDAI (r=0.331; P<0.0001 based on 136 
datasets from all 59 patients) (Supplementary Figure 4). Improvements in both treatment 
groups were similar but modest – falling from median (IQR) 497 (265-726) ug/g at week 0 to 
331.5 (89-600)ug/g at week 10 with antibiotics/hydroxychloroquine (P=0.03) and from 
573.5 (307-924)ug/g at week 0 to 454 (167-634)ug/g at week 10 with budesonide (P=0.15) 
(Supplementary Figure 5). Based on per protocol analysis, 10/17 patients receiving 
antibiotics/hydroxychloroquine achieved faecal calprotectin <250 ug/g at week 10 




There were 100 adverse events affecting 34 of 39 (87%) patients receiving 
antibiotics/hydroxychloroquine and 55 adverse events in 31 of 39 (79%) patients receiving 
budesonide (Table 5). Withdrawals by 10 weeks for adverse events were seen in 15 
receiving antibiotics/hydroxychloroquine and 6 budesonide. Nausea affected 24 of 39 (62%) 
receiving antibiotics/hydroxychloroquine but was usually transient and only led to 
discontinuation of therapy in two; photosensitivity affected 11 of 39 (28%) even though all 
patients were warned to use high sun protective factor creams and minimise exposure and 
led to discontinuation of therapy in three; tendinopathy or arthralgia affected 7 of 39 (18%) 
and tendinopathy led to discontinuation in two but resolved without tendon rupture; 6 of 
39 (15%) developed candidiasis of whom two received topical antifungals. Five patients 
receiving antibiotics/hydroxychloroquine suffered severe adverse events including two 
drug-related (vomiting and photosensitivity) and three unrelated – a fall in an elderly 
patient complicated by rhabdomyolysis, perianal abscess, and non-fatal pulmonary 





In this open-label study we found no significant difference in remission or response rates at 
10, 24, or 52 weeks between the antibiotic/hydroxychloroquine combination and a standard 
12 week course of budesonide. The study was not powered for non-inferiority. On initial 
therapy there was a non-significant trend towards better results at 10 weeks with 
budesonide however, with crossover data included, similar remission and response rates 
were seen with both treatments. The 24 week data also showed no significant difference 
between treatment groups when assessed on intention to treat using pre-defined 
thresholds for statistical significance. However, when assessed per protocol, the results 
were encouraging for the antibiotic/hydroxychloroquine combination with 9 of 24 in 
remission at 24 weeks. Sustained remission to 24 weeks was only seen in one of 32 (per 
protocol) budesonide-treated patients – who had of course tailed off their therapy by 12 
weeks. This might sound “unfair” given that the doxycycline and hydroxychloroquine were 
continued through to 24 weeks but is justified given that the efficacy of budesonide is only 
sustained for around three months, with longer maintenance ineffective [24]. The 52 week 
data showed a modest signal to support prolonged efficacy with the 
antibiotic/hydroxychloroquine combination, with 4/23 in remission at that time point on per 
protocol analysis. Patients who crossed over to the antibiotic/hydroxychloroquine 
combination fared better (remission at 10 weeks in 5/12, 42%; remission maintained to 24 
weeks in 4/12, 33%; and remission maintained to 52 weeks in 2/12, 17%) raising the 
possibility that prior steroids followed by antibiotics/hydroxychloroquine might have been 
better than either treatment alone. 
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Remission rates with budesonide were lower than predicted, 8/32 (25%) at 10 weeks 
compared with 53% in the original trial by Rutgeerts et al [22]. The reason for this is unclear, 
but might in part be due to the inclusion of patients with isolated colonic Crohn’s disease in 
the current study (Supplementary Table 1). When these are excluded, the remission rate, 
including crossover, with budesonide was 9/24 (38%) when analysed per protocol at 10 
weeks. Average CDAI at baseline was 277 which is almost identical to that in the Rutgeerts 
et al trial (275). CRP was lower (median 8.5 mg/l compared with mean 25 mg/l in Rutgeerts 
et al). Moreover most (7/8; 87.5%) of the patients who were in remission at 10 weeks with 
budesonide  had relapsed by 24 weeks off therapy.  
 
The patient global assessment (IBD10) correlated very well with CDAI scores, confirming 
that an IBD10 score of 8 is equivalent to a CDAI of 150 [23], and showed treatment 
responses comparable to the primary outcome data, with improvements by 10 weeks 
similar for both treatment groups. There was a much weaker correlation between faecal 
calprotectin and CDAI and improvements seen in both treatment arms were modest. Faecal 
calprotectin is known to correlate better with mucosal healing and 4 of 9 patients in 
remission at 24 weeks had faecal calprotectin <70ug/g, one of the lower proposed cut-off 
values for indicating likely endoscopic remission. 
 
Prevalence of mucosal E. coli in Crohn’s disease ranges from 21 to 63% of cases [1]. The 
antibiotic/hydroxychloroquine combination would also be effective against other organisms, 
particularly Gram negative bacteria, that could invade the gut and replicate within 
macrophages. We had hoped that serological testing might identify patients more likely to 
be affected by E. coli and thus predict response to antibiotics/hydroxychloroquine. OmpC is 
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an outer membrane porin protein found in Gram negative organisms including E. coli but 
only 6 of 50 patients tested positive for OmpC antibody. Anti-Saccharomyces cerevisiae 
(baker’s yeast) antibody (ASCA) is the best established antibody associated with Crohn’s 
disease. Its origin is unclear as baker’s yeast is not the only source of its antigen, an 
oligomannan with a specific mannose alpha 1,3 mannose alpha 1,2 mannose terminal 
sequence [25,26]. Other possible microbial sources include Candida albicans and 
Mycobacterium avium subspecies paratuberculosis [27,28]. There is an intriguing possibility 
that a key ASCA antigen could be the mannan receptor for Gram negative bacterial fimH on 
glycoprotein 2 (GP2) on microfold (M) cells [29]. M cells are the initial sites for bacterial 
invasion and are also thought to be the sites of the initial lesions in Crohn’s disease. There is 
considerable overlap between ASCA and anti-GP2 serology in Crohn’s disease sera [30]. 
Moreover, although the mannan on GP2 has yet to be characterised, the bladder equivalent 
of GP2 is uroplakin and its mannan receptor for fimH expressed by uropathogenic E. coli is 
oligomannose-3 which contains the same terminal mannose alpha 1,3 mannose sequence 
as the ASCA epitope [31]. It therefore seemed plausible that ASCA positivity might identify 
Crohn’s disease patients with E. coli invasion. However, in this study there was no 
correlation between ASCA, either separately, or combined with ompC positivity, and 
response to the antibiotic/hydroxychloroquine combination.   
 
There is a good case for considering isolated colonic Crohn’s disease as a separate condition 
from Crohn’s disease affecting the small intestine [32,33]. There has also been a suggestion 
that it might respond better to antibiotics [32]. In this study patients with isolated colonic 
disease showed no significant difference in response to antibiotics/hydroxychloroquine. 
Careful analysis of the nine patients who were in remission at 24 weeks on the 
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antibiotic/hydroxychloroquine combination again failed to show association with phenotype 
or serotype. It is possible that a more specific bacterial DNA-based technique is needed, 
possibly based on detection of circulating Gram negative bacterial DNA which has been 
shown to predict relapse [34].  
 
Side effects were an issue with the ciprofloxacin, doxycycline, hydroxychloroquine 
combination, particularly in the first month when patients were taking all three drugs. 
Nausea was common but was usually very transient but photosensitivity (all three drugs are 
known to cause this) and Achilles tendon pain were also issues. Hydroxychloroquine is 
associated with risk of retinopathy but this is related to cumulative dosage, usually over 
years of therapy. All patients were screened prior to trial entry for any history of visual 
impairment not corrected by wearing glasses and by visual acuity testing repeated at 10 
weeks or early withdrawal. No patient failed screening on these grounds. One patient was 
withdrawn because of transient blurred vision but this was thought unlikely to be related to 
the hydroxychloroquine. Six patients developed candidiasis but none stopped trial 
medication because of this. 
 
We believe that the signals of efficacy seen with the antibiotic/hydroxychloroquine 
combination, particularly the longer-term remissions, justify further study. It is unfortunate 
that neither phenotypic information or serology seem to identify patients likely to respond. 
It is possible that a DNA-based approach probing for E. coli or other Gram negative 
organisms on faecal or peripheral blood samples might better identify patients likely to 
respond but this was beyond the funding available for this study. Alternatives deserving 
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further study include serological testing for serum anti-E. coli /salivary CEACAM6 index [35] 
and quantification of faecal IgA-coated E. coli [36]. 
 
The choice of antibiotics is also an issue. Ciprofloxacin was selected mainly because it 
showed the greatest in vitro potency against E. coli replicating within macrophages [11]. It 
does however seem to have added considerably to side-effects. A future trial might be 
confined to long term therapy with the doxycycline hydroxychloroquine combination. This 
has proved successful in Whipple’s disease [19]and Q fever [18]. Alternative strategies 
targeting the altered Crohn’s disease microbiota could include bacteriophages or bacterial 
function-editing substrates [37].  
 
Conclusion 
Further study of long term doxycycline plus hydroxychloroquine as an adjunct to biologic 
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Table 1 Demographic data 
  Baseline: Antibiotic / 
hydroxychloroquine 














Total   
 n=27 n=12 n=39 n=32 n=7 n=39   
Male 18 (66.6%) 9 (75.0%) 27 (69.2%) 18 
(56.3%) 
4 (57.1%) 22 
(56.4%) 
0.44 0.35 













6 (1-11) 4 (1.5-7.5) 5 (1-10) 3.5 (1.5-
12) 
10 (2-19) 5 (2-13) 0.89 0.64 




A1 (</=16) 2 (7.4%) 1 (8.3%) 3 (3.3%) 3 (9.4%) 0 3 (7.8%) 1.00 1.00 
A2 (17-40) 15 (55.6%) 5 (41.7%) 20 (51.3%) 15 
(46.9%) 
4 (57.1%) 19 
(48.7%) 
0.60 1.00 
A3 (>40) 10 (37.0%) 6 (50.0%) 16 (15.4%) 14 
(43.8%) 







L1 8 (29.6%) 2 (16.7%) 10 (25.6%) 8 (25.0%) 3 (42.9%) 11 
(28.2%) 
0.77 1.00 
L2 (stratified before 
randomisation) 
8 (29.6%) 3 (25.0%) 11 (28.2%) 11 
(34.4%) 
1 (14.3%) 12 
(30.8%) 
0.78 1.00 
L3 11 (40.7%) 7 (58.3%) 18 (46.2%) 13 
(40.6%)  





19 (70.4%) 10 
(83.3%) 
29 (74.4%) 24 
(75.0%) 
4 (57.1%) 28 
(71.8%) 
0.77 1.00 
L4 (proximal small 
bowel disease) 
1 (3.7%) 0 1 (2.6%) 0 1 (14.3%) 1 (2.6%) 0.46 1.00 
Perianal disease 4 (14.8%) 1 (8.3%) 5 (12.8%) 3 (9.4%) 2 (28.6%) 5 
(12.8%) 
0.69 1.00 
Type:   
B1  23 (85.2%) 9 (75.0%) 32 (82.1%) 26 
(81.3%) 
5 (71.4%) 31 
(79.5%) 
0.74 1.00 
B2 (stricturing) 4 (14.8%) 2 (16.7%) 6 (15.4%) 4 (12.5%) 2 (28.6%) 6 
(15.4%) 
0.69 1.00 
















<3)(median [IQR])  
9 (5-26) 5.5 (5-
11.5) 
9 (5-20) 8 (5-22) 
(n=31) 






































Table 2 Response to initial therapy course (Primary endpoint data in bold) 
 
















AB/HCQ 2/27 2/27  










Budesonide 8/32 1/32 1/32 11/32 8/32 
Per protocol analysis 
AB/HCQ 2/20 2/17 






































AB/HCQ 7/39 6/39 
(plus 3 10wk 
responders in rem 
@ 24 weeks)  
3/39 
(plus 1 10wk 
responder in rem 
@ 52 weeks; plus 
1 clin rem but 
withdrawn UTI) 
15/39 8/39 
Budesonide 10/39 1/39 1/39  13/39 9/39 
Per protocol analysis 
AB/HCQ 7/27 6/24 
(plus 3 10wk 
responders in rem 





(plus 1 10wk 
responder in rem 
@ 52 weeks; plus 
1 clin rem but 
withdrawn UTI) 
15/27 8/30 






Table  4. Phenotypic and serological features of the 9 patients who achieved remission 
at 24 weeks on antibiotics/hydroxychloroquine.  
 
















ASCA OmpC FlaX CBir Fla2 
M 21 10 A1L1
B1 
N Initial N N 8 N N N N N 
F 30 1 A2L3
B1 
Y Initial Y Y 74 N N Y N Y 
M 54 6 A2L3
B1 
Y Initial N Y 9 N N N N N 
M 59 0.5 A3L1
B1 
N Initial N N 9 N N Y N N 
F 37 1 A2L3
B1 
Y Initial N Y 7 N N N N N 
M 89 5 A3L2
B1 
Y Crossover Y N 30 N Y N N Y 
M 47 5 A3L1
B2P 
N Crossover Y N 6 Y N N N N 
M 29 16 A1L3
B1 
Y Crossover N N 5 Y N N Y N 
M 27 1 A2L2
B1 




Table 5. Adverse events (AEs) 
  
             Budesonide            Antibiotics/HCQ 
     n=39 n=39 
Subjects with any AEs    31 34 
Intensity of worst AE     
Mild     12 8 
Moderate     18 19 
Severe     1 5 
Subjects with AEs leading to 
discontinuation  2 11 
       
Adverse events by system     
Total     55 100 
Gastrointestinal      
 Nausea +/-vomiting   6 24 
 Diarrhoea (worsened)   7 9 
 Reflux/heartburn   1 4 
 Anorexia    0 2 
 
Abdominal pain 
(worsening)  3 2 
 Proctalgia    1 2 
 Tenesmus (worsened)   2 1 
 Rectal bleeding   2 0 
General disorders      
 Mouth ulcers   3 1 
 Fatigue    2 1 
 Hair loss    1 1 
Infections and infestations     
 Respiratory   7 4 
 UTI    0 2 
 Candidiasis   0 6 
Nervous system disorders     
 Sleep disturbance   6 8 
 Headache    4 5 
 Mood disturbance   5 3 
 Dizziness    1 1 
 Panic    1 1 
Skin and subcutaneous disorders     
 Photosensitivity   0 8 
 Rash    0 3 
 Acne    1 1 
 Eczema (worsening)   1 1 
Respiratory, thoracic, and mediastinal 
disorders   
 Pulmonary embolism   0 1 
 Dyspnoea    0 1 
Musculoskeletal disorders     
 Tendopathy   0 2 
 Cramp    1 1 
 Arthralgia    0 5     
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Legends to Figures 
Figure 1. Study design. 
Figure 2. Remission rates at 10, 24, 52 weeks, including crossover data: (a) Intention to 




Figure 1. Consort flow diagram.  
Figure 2. Correlation between CDAI and patient global index (IBD10)  - 219 datasets from 
the 59 patients. 
Figure 3. Patient global index (IBD10) scores including crossover (per protocol). P values 
for 0 vs 10 weeks by Wilcoxon Signed Rank test on paired samples. 
Figure 4. Correlation between CDAI and faecal calprotectin (136 datasets from 59 
patients)  
Figure 5. Faecal calprotectin levels including crossover (per protocol). P values for 0 vs 
10 weeks by Wilcoxon Signed Rank test on paired samples. 




Supplementary Table 1. Response to therapy including crossover in the subgroup of 





    
     
     
     
  
     
   
   
    
    
    
    
     
   
     
    
    
    
    
     
     
   
 
 





















Budesonide 1/12 0/12 0/12  4/12 2/12 
Per protocol analysis 





Budesonide 1/10 0/10 0/10 4/10 2/12 
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Supplementary Table 2. 









Positive for ASCA 













AB/HCQ 3/11 2/11 1/11 3/11 4/11 
Budesonide 5/17 0/17 0/17  6/17 2/17 
Per protocol analysis 
AB/HCQ 4/21 4/21 




2/21 11/21 4/21 
Budesonide 3/15 1/15 1/15 4/15 4/15 
Negative for ASCA 













AB/HCQ 4/21 4/21 
(+3 10 week 
responders in 
rem @ 24 
weeks) 
2/21 11/21 4/21 
Budesonide 3/15 1/15 1/15 4/15 4/15 
Per protocol analysis 
AB/HCQ 4/16 4/15 
(+3 10 week 
responders in 
rem @ 24 
weeks) 
2/14 
(+1 10 week 
responder in 
rem @ 52 
weeks) 
11/16 4/17 
Budesonide 3/13 1/11 1/11 4/13 4/13 
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(b) Response to therapy including crossover in patients positive versus negative for ASCA 























Positive for ASCA and/or OmpC 













AB/HCQ 4/15 3/15 1/15 5/15 5/15 
Budesonide 6/19 0/19 
P=0.076 
0/19  7/19 4/19 
Per protocol analysis 
AB/HCQ 4/9 3/8 1/7 5/9 5/11 
Budesonide 6/17 0/16 
P=0.028 
0/16 7/17 4/19 
Negative for both ASCA and OmpC 
Intention to treat analysis 












AB/HCQ 3/17 3/17 2/17 9/17 3/17 
Budesonide 2/13 1/13 1/13 3/13 2/13 
Per protocol 
analysis 
     
AB/HCQ 3/13 3/13 2/13 9/14 3/15 
Budesonide 2/12 1/12 1/11 3/12 2/11 
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Positive for FlaX 
Intention to treat analysis 










AB/HCQ  1/6 0/6 0/6 3/6 1/6 
Budesonide 4/12 1/12 1/12  5/12 2/12 
Per protocol analysis 
AB/HCQ 1/5 0/5 0/4 3/5 1/5 
Budesonide 4/11 1/11 1/11 5/11 2/11 
Negative for FlaX 
Intention to treat analysis 







response 10 w 
Remission 4 w 
AB/HCQ 6/26 6/26 3/26 11/26 7/26 
Budesonide 4/20 0/20 0/20 5/20 4/20 
Per protocol 
analysis 
     
AB/HCQ 6/18 6/17 3/16 11/18 7/21 
Budesonide 4/18 0/17 0/16 5/18 4/19 
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Suppl Fig 5 
 
 
